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Association of telomerase expression with recurrence of sacral chordoma
Originated from the remnants of the notochord in the process of fetal development, chordoma is a rare, slow growing and locally invasive low-grade malignant tumor with an annual incidence rate of 1/8 000 000 [1] . There are no standard prognostic markers in this disease. This retrospective study assessed telomerase in 20 patients of sacral chordoma (10 males and 10 females, aged 18-77 years). The samples of tumor tissues were obtained intraoperatively from all the patients, and samples of normal tissues 3 cm adjacent to the tumors were from seven patients. Follow-ups were scheduled every 3 to 6 months. Recurrence was evaluated from clinical examinations and imaging. Surgical resection samples were fixed in formalin and embedded in paraffin block before sliced into 4 μm in thickness for telomerase staining. Samples of colorectal cancer were used as the positive control and phosphate-buffered saline (PBS) was as the negative control. The scale of percentage of the positive cell number was defined as 0, 0%; 1, 1-25%; 2, 26-50% and 3, >50%. The scale of the color intensity was 0, none; 1, light brown; 2, brown and 3, dark brown. The overall score was summarized from both scales as 0, negative; 1-4, weakly positive and 5-6, strongly positive.
Among the 20 patients, eleven of them had relapse. Recurrence rates of 1, 3, 5 and 10 years were 5, 25, 55 and 90%, respectively. Telomerase expression was positive in all 20 cases (11 strongly positive and 9 weakly positive) (Fig. 1) . The peritumoral normal tissues had telomerase expression negative. Positive expression of telomerase with chordoma recurrence was significantly higher than those without recurrence (P = 0.003). Telomerase expression in relapse was significantly different from that without recurrence (P < 0.001).
To our knowledge, 20 patients are the largest clinical series in sacral chordoma. Recurrence after surgical resection is a common occurrence. Our study demonstrated the association of telomerase expression with recurrence, suggesting that the telomerase expression could be another predictor of recurrence and survival.
